AstraZeneca sold global right of Imdur to China Medical System Holdings
AstraZeneca announced that it has handover global rights of Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement,
AstraZeneca will receive $190 million for the rights to Imdur. Imdur is a mature medicine for the prevention of angina in patients with heart disease.
Imdur is a mature medicine for the prevention of angina in patients with heart disease and achieved global sales outside the US of $57 million in 2015. Income from the agreement will be reported as Core Other Operating Income.